Stockscreener 앱 받기
7.17
2.43%
0.17
시간 외 거래:
7.15
-0.02
-0.28%
전일 마감가:
$7.00
열려 있는:
$7.1
하루 거래량:
3.62M
Relative Volume:
0.45
시가총액:
$1.16B
수익:
$847.25M
순이익/손실:
$-284.86M
주가수익비율:
-3.131
EPS:
-2.29
순현금흐름:
$-112.35M
1주 성능:
+2.87%
1개월 성능:
+11.86%
6개월 성능:
-18.62%
1년 성능:
-48.23%
1일 변동 폭
$6.96
$7.18
1주일 범위
$6.71
$7.18
52주 변동 폭
$5.01
$17.81
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.17 | 1.13B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
What analysts say about Novavax Inc. stockExceptional trading performance - Autocar Professional
Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach - insights.citeline.com
(NVAX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Is Novavax Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com
What drives Novavax Inc. stock priceOutstanding risk-reward balance - PrintWeekIndia
Novavax Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - PrintWeekIndia
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax’s Latest Vaccine Study: Key Insights for Investors - TipRanks
Over 31,000 Investors Are Getting Payouts from Novavax — Check What You Might Be Missing - TradingView
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine - MSN
Why Novavax Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
Novavax (NVAX) Rises Higher Than Market: Key Facts - Yahoo Finance
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
Novavax's Dual Vaccine Strategy: Navigating Near-Term Hurdles to Long-Term Growth Potential - AInvest
Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth (NASDAQ:NVAX) - Seeking Alpha
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet - Yahoo Finance
Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors with Substantial Losses to Contact the Firm - ACCESS Newswire
(NVAX) Technical Data - news.stocktradersdaily.com
Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating - MSN
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks - Benzinga
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval - Benzinga
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now? - Yahoo Finance
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease - MedCity News
Novavax Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Novavax jumps 15% on COVID shot nod, among 14 FDA approvals in May - BioWorld MedTech
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus
Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):